mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say
MaysonL Sunday, January 25, 2026
Summary
A phase 2 clinical trial of an mRNA-based cancer vaccine, developed by Moderna and Merck, has shown long-term protection against melanoma recurrence, with 44% of vaccine recipients remaining recurrence-free after 5 years of follow-up. The results suggest the potential for mRNA vaccines in cancer treatment.
18
1
Summary
arstechnica.com